LRIG1 is a potent inhibitor of GBM growth in clinically-relevant experimental glioma models, largely independent of EGFR status (Johansson et al., 2013) and is thought to restrict proliferation and aggressiveness of GSCs (Mao et al., 2017). Here, LRIG1 is linked to glioma.